IP Library Patent Application 14189801
Patent Application
App. No. 14/189,801

HORMONE DELIVERY SYSTEM AND METHOD

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/189,801
Abstract

A hormone delivery system and method are provided for administering bioidentical human hormones using a combination of modalities for the treatment of human physiological conditions.

Claims (15)

1 . A method of delivering hormones to a patient, which method comprises the steps of:

providing a predetermined quantity of human hormones;

determining a hormone deficiency in the patient;

matching a hormone with the determined hormone deficiency;

delivering progesterone and estrogen to the patient in a sequential format following the human physiological twenty-eight day menstrual cycle using a modality comprising transdermal absorption of said estrogen and oral absorption of said progesterone; and

thereby treating hormone imbalances or deficiencies associated with peri-menopause, menopause and post-menopause.

2 . The method according to claim 1 , wherein said absorption of said progesterone comprises micronized progesterone in a form chosen from the list including: a capsule, a sublingual, a troche, and a pill.

3 . The method according to claim 1 , wherein said estrogen is delivered to the patient throughout the entire twenty-eight day menstrual cycle.

4 . The method according to claim 3 , wherein said progesterone is delivered to the patient from day 10 to day 28 of the menstrual cycle.

5 . The method according to claim 3 , wherein said progesterone is delivered to the patient from day 11 to day 28 of the menstrual cycle.

6 . The method according to claim 3 , wherein said progesterone is delivered to the patient from day 12 to day 28 of the menstrual cycle.

7 . The method according to claim 3 , wherein said progesterone is delivered to the patient from day 13 to day 28 of the menstrual cycle.

8 . The method according to claim 3 , wherein said progesterone is delivered to the patient from day 14 to day 28 of the menstrual cycle.

9 . The method according to claim 1 , wherein said progesterone is provided at an amount between 20 mg and 300 mg per dose.

10 . The method according to claim 1 , wherein said estrogen is provided at an amount between 0.25 mg and 1.0 mg per dose.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2014
From: BAUCOM, KARAN Y.
To: BAUCOM INSTITUTE FOR LONGEVITY AND LIFE ENHANCEMENT, INC.
Reel/Frame 033335/0859 →